Benefits / risks for fibrinolytic therapy in intermediate-risk PE

Benefits/Risks for fibrinolytic therapy in intermediate-risk PE

(HealthDay)—A single intravenous bolus of tenecteplase reduces early death and hemodynamic decompensation in normotensive patients with intermediate-risk pulmonary embolism, but increases the risk of major hemorrhage and stroke, according to a study published in the April 10 issue of the New England Journal of Medicine.

Guy Meyer, M.D., from the Hôpital Européen Georges Pompidou in Paris, and colleagues randomized 1,005 normotensive patients with intermediate-risk pulmonary embolism due to right ventricular dysfunction and myocardial injury to tenecteplase plus heparin or placebo plus heparin. A composite of death or hemodynamic decompensation (or collapse) within seven days of randomization marked the primary outcome.

The researchers found that death or hemodynamic decompensation occurred in 2.6 percent of the 506 patients in the tenecteplase group versus 5.6 percent of the 499 patients in the placebo group (odds ratio, 0.44; P = 0.02). Death occurred in the first seven days in six patients in the tenecteplase group and nine patients in the placebo group (P = 0.42). Extracranial bleeding occurred in 32 patients in the tenecteplase group and six patients in the (6.3 versus 1.2 percent; P < 0.001). In the tenecteplase group, 12 patients had a stroke (2.4 percent), of which 10 were hemorrhagic, compared to one patient with in the control group (P = 0.003).

"In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke," the authors write.

The study was funded in part by a grant from Boehringer Ingelheim.


Explore further

Clot-busting drug benefits intermediate-risk patients with pulmonary embolism

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: New England Journal of Medicine

Copyright © 2014 HealthDay. All rights reserved.

Citation: Benefits / risks for fibrinolytic therapy in intermediate-risk PE (2014, April 11) retrieved 28 January 2020 from https://medicalxpress.com/news/2014-04-benefits-fibrinolytic-therapy-intermediate-risk-pe.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments